Supercharged immune cells take on kidney cancer in new trial
NCT ID NCT07551349
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a one-time infusion of specially engineered immune cells (CAR-NK cells) that target two proteins, CD70 and CAIX, found on kidney cancer cells. The study includes 36 adults with advanced clear cell renal cell carcinoma that has worsened after standard treatments. Participants also receive chemotherapy beforehand to help the cells work. The goal is to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered immune cells (CAR-NK cells) targeting CD70 and CAIX, plus chemotherapy (fludarabine) to prepare the body
- What this could lead to
- If successful, this could lead to a new treatment option for advanced kidney cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 36 participants, so results may not apply broadly. There are risks from the chemotherapy and the immune cells, including potential liver side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.